Subsidiary’s Tranexamic Acid Sodium Chloride Injection Receives Drug Registration Certificate
August 13, 2026
Source: drugdu
27
On August 7th, Tianjin Pharmaceutical Co., Ltd.(600488.SH) announced that its subsidiary, Hubei Jinyao, received a Drug Registration Certificate for Tranexamic Acid Sodium Chloride Injection issued by the National Medical Products Administration. This drug is mainly used for various types of bleeding caused by acute or chronic, localized or systemic primary fibrinolysis. It was registered as a Class 3 chemical drug, and its approval is considered as passing the consistency evaluation of generic drug quality and efficacy. The approval of this drug will enrich the company's pharmaceutical product portfolio and have a positive impact on expanding the domestic pharmaceutical market and improving its performance.
https://finance.eastmoney.com/a/202608073835167227.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- A well-known generic drug company recalls 10 types of eye drops. August 13, 2026
- Big news! Zhejiang pharmaceutical company targets 500 million yuan lipid-lowering blockbuster drug August 13, 2026
- Lenvatinib Mesylate Capsules Receive Drug Registration Certificate August 13, 2026
- Subsidiary’s self-developed Class 1 innovative drug, bemosubalimab injection, in combination therapy, has been approved for marketing. August 13, 2026
- Hanyu Pharmaceutical has licensed 3SBio’s Smegglutide injection to commercialize the product, with sales milestones reaching up to 145 million yuan. August 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
